EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies

Danai Dima iD, Nerea Lopetegui-Lia, Olisaemeka Ogbue, Bennett Osantowski, Fauzia Ullah, Xuefei Jia, Jung Min Song, Brian Gastman, James Isaacs, Lucy Boyce Kennedy, Pauline Funchain

Cancer Medicine · 2024-06 · 13 (12)

DOI: 10.1002/cam4.7257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.06.2024. Verfasst von Danai Dima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Melanoma, Neoplasm Staging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse, for whom best management is unclear. The aim of our study was to assess the efficacy, and safety of adj anti‐PD1 IO and TT in a real‐world cohort of patients with resected stage III melanoma, and further delineate patterns of recurrence and treatment strategies.

Methods

We retrospectively analyzed 130 patients who received adj therapy (100 anti‐PD1 IO and 30 TT).

Results

At a median follow‐up of 30 months, median relapse‐free survival (RFS) was 24.6 (95% CI, 17–not reached [NR]) versus 64 (95% CI, 29.5–NR) months for the TT and IO groups, respectively ( p = 0.26). Median overall survival (OS) was NR for either subgroup. At data cutoff, 77% and 82% of patients in TT and IO arms were alive. A higher number of grade ≥3 treatment‐related adverse events (AEs) were noted in the IO group (11% vs. 3%), however, a higher proportion of patients permanently discontinued adj therapy in the TT group (43% vs. 11%) due to toxicity. Strategies at relapse and outcomes were variable based on location and timing of recurrence. A significant number of patients who relapsed after adj IO received a second round of IO. Among them, patients who were off adj IO at relapse had superior second median RFS (mRFS2), compared to those who relapsed while on adj IO; mRFS2 was NR versus 5.1 months (95% CI, 2.5–NR), respectively, p = 0.02.

Conclusion

In summary, both TT and IO yielded prolonged RFS in a real‐world setting, however, longer follow‐up is needed to determine any potential OS benefit. Adj therapy, particularly TT, may not be as well tolerated as suggested in clinical trials, with lower completion rates (59% vs. 74%) in a real‐life setting. Overall, patients who relapse during adj therapy have poor outcomes, while patients who relapse after discontinuation of adj IO therapy appear to benefit from IO re‐treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasm StagingHumansFemaleMaleMiddle AgedRetrospective StudiesAgedChemotherapy, AdjuvantAdultNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsSkin NeoplasmsTreatment OutcomeMolecular Targeted TherapyImmunotherapyAged, 80 and over

Stichwörter der Autor:innen

adjuvant therapyadverse eventsimmunotherapystage III melanomatargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Biostatistics, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Plastic Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Danai Dima

Zitieren

APA

Dima, D., Lopetegui-Lia, N., Ogbue, O., Osantowski, B., Ullah, F., Jia, X., Song, J. M., Gastman, B., Isaacs, J., Kennedy, L. B., & Funchain, P. (2024). Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. Cancer Medicine, 13(12). https://doi.org/10.1002/cam4.7257

Vancouver

Dima D, Lopetegui-Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, et al. Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. Cancer Medicine. 2024;13(12). doi:10.1002/cam4.7257

BibTeX
@article{Dima2024,
  author = {Dima, Danai and Lopetegui-Lia, Nerea and Ogbue, Olisaemeka and Osantowski, Bennett and Ullah, Fauzia and Jia, Xuefei and Song, Jung Min and Gastman, Brian and Isaacs, James and Kennedy, Lucy Boyce and Funchain, Pauline},
  title = {Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {12},
  doi = {10.1002/cam4.7257}
}
Kostenlos starten →